Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with...

Area of Science:

• Hepatology
• Oncology
• Virology

Background:

• Hepatocellular carcinoma (HCC) recurrence is common post-treatment, leading to poor prognosis.
• New tumor foci frequently develop even after surgical or medical HCC treatment.

Purpose of the Study:

• To evaluate if combined tumor ablation and interferon therapy reduce new HCC foci occurrence.
• To determine if this combined approach improves patient survival rates.

Main Methods:

• A randomized, controlled study was conducted at a university hospital.
• 74 patients with compensated cirrhosis and early-stage HCC received percutaneous ethanol injection therapy.
• 49 patients received adjuvant interferon therapy, while 25 did not.

Main Results:

• Interferon therapy showed sustained biochemical and virologic responses in a subset of patients.
• While first HCC recurrence rates were similar, second/third recurrence rates appeared lower with interferon.
• Five-year survival was 68% with interferon vs. 48% without; seven-year survival was 53% vs. 23%.

Conclusions:

• Interferon therapy following ethanol ablation may improve survival in select HCC patients.
• This approach is particularly relevant for patients with chronic hepatitis C.